NEW YORK — Effective targeted therapies and immunotherapies for melanoma are likely to also be effective for the treatment of brain metastases, according to a presenter at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.
Conferences
Adjuvant ipilimumab prolongs RFS in stage III melanoma
NEW YORK — Patients with high-risk stage III melanoma who received ipilimumab after complete resection demonstrated prolonged RFS compared with patients who received placebo, according to phase 3 study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.
Balance between benefits, harms key to limiting overdiagnosis in melanoma screening
Although overdiagnosis is common in cancer screening, it is not excessive if the benefits outweigh the harms, according to a presenter at the HemOnc Today Melanoma and Cutaneous Malignancies meeting.
PHP may increase survival in patients with liver metastases
Percutaneous hepatic perfusion increased hepatic progression free and overall survival rates in patients with liver metastases from melanoma vs. patients who underwent yttrium-90 therapy, according to data presented at the 2015 Society of Surgical Oncology Annual Cancer Symposium.